Suppr超能文献

哮喘治疗期间不良反应的预测因素因结局定义而异。

Predictors of poor response during asthma therapy differ with definition of outcome.

机构信息

Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Pharmacogenomics. 2009 Aug;10(8):1231-42. doi: 10.2217/pgs.09.86.

Abstract

AIMS

To evaluate phenotypic and genetic variables associated with a poor long-term response to inhaled corticosteroid therapy for asthma, based independently on lung function changes or asthma exacerbations.

MATERIALS & METHODS: We tested 17 phenotypic variables and polymorphisms in FCER2 and CRHR1 in 311 children (aged 5-12 years) randomized to a 4-year course of inhaled corticosteroid during the Childhood Asthma Management Program (CAMP).

RESULTS

Predictors of recurrent asthma exacerbations are distinct from predictors of poor lung function response. A history of prior asthma exacerbations, younger age and a higher IgE level (p < 0.05) are associated with recurrent exacerbations. By contrast, lower bronchodilator response to albuterol and the minor alleles of RS242941 in CRHR1 and T2206C in FCER2 (p < 0.05) are associated with poor lung function response. Poor lung function response does not increase the risk of exacerbations and vice versa (p = 0.72).

CONCLUSION

Genetic and phenotypic predictors of a poor long-term response to inhaled corticosteroids differ markedly depending on definition of outcome (based on exacerbations vs lung function). These findings are important in comparing outcomes of clinical trials and in designing future pharmacogenetic studies.

摘要

目的

根据肺功能变化或哮喘恶化的情况,独立评估与吸入皮质类固醇治疗哮喘长期疗效不佳相关的表型和遗传变量。

材料与方法

我们在儿童哮喘管理计划(CAMP)中对 311 名 5-12 岁儿童进行了为期 4 年的吸入皮质类固醇治疗,检测了 17 个表型变量和 FCER2 和 CRHR1 中的多态性。

结果

哮喘恶化的预测因素与肺功能反应不佳的预测因素不同。既往哮喘恶化史、年龄较小和 IgE 水平较高(p<0.05)与哮喘恶化相关。相比之下,沙丁胺醇支气管扩张反应较低以及 CRHR1 中的 RS242941 次要等位基因和 FCER2 中的 T2206C(p<0.05)与肺功能反应不佳相关。肺功能反应不佳不会增加恶化的风险,反之亦然(p=0.72)。

结论

吸入皮质类固醇治疗长期疗效不佳的遗传和表型预测因素因结局定义(基于恶化与肺功能)而异。这些发现对于比较临床试验结果和设计未来的药物遗传学研究非常重要。

相似文献

1
Predictors of poor response during asthma therapy differ with definition of outcome.
Pharmacogenomics. 2009 Aug;10(8):1231-42. doi: 10.2217/pgs.09.86.
2
FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children.
Allergy. 2011 Dec;66(12):1546-52. doi: 10.1111/j.1398-9995.2011.02701.x. Epub 2011 Sep 29.
3
FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma.
J Allergy Clin Immunol. 2007 Dec;120(6):1285-91. doi: 10.1016/j.jaci.2007.09.005. Epub 2007 Nov 5.
4
FCER2 T2206C variant associated with FENO levels in asthmatic children using inhaled corticosteroids: The PACMAN study.
Clin Exp Allergy. 2019 Nov;49(11):1429-1436. doi: 10.1111/cea.13460. Epub 2019 Aug 26.
7
Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD.
Respirology. 2009 Mar;14(2):260-3. doi: 10.1111/j.1440-1843.2008.01425.x. Epub 2008 Dec 11.
9
Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms.
J Allergy Clin Immunol. 2008 Jun;121(6):1510-3. doi: 10.1016/j.jaci.2008.04.015.

引用本文的文献

1
Defining the Differential Corticosteroid Response Basis from Multiple Omics Approaches.
Int J Mol Sci. 2024 Dec 19;25(24):13611. doi: 10.3390/ijms252413611.
2
Asthma exacerbations and eosinophilia in the UK Biobank: a genome-wide association study.
ERJ Open Res. 2024 Jan 8;10(1). doi: 10.1183/23120541.00566-2023. eCollection 2024 Jan.
3
[The correlation between FCER2 gene polymorphism and the efficacy of inhaled corticosteroids in patients with chronic rhinosinusitis].
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 Nov;37(11):856-863. doi: 10.13201/j.issn.2096-7993.2023.11.002.
4
Responsiveness of Inhaled Corticosteroid Treatment in Children with Asthma: The Role of rs242941 Polymorphism of CRHR1 Gene.
Pulm Ther. 2023 Mar;9(1):127-137. doi: 10.1007/s41030-022-00205-9. Epub 2022 Dec 2.
5
Pharmacogenomics of Leukotriene Modifiers: A Systematic Review and Meta-Analysis.
J Pers Med. 2022 Jun 29;12(7):1068. doi: 10.3390/jpm12071068.
6
Genetic Determinants of Poor Response to Treatment in Severe Asthma.
Int J Mol Sci. 2021 Apr 20;22(8):4251. doi: 10.3390/ijms22084251.
7
Drug Repurposing to Treat Glucocorticoid Resistance in Asthma.
J Pers Med. 2021 Mar 3;11(3):175. doi: 10.3390/jpm11030175.
8
Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy.
Pharmgenomics Pers Med. 2020 Aug 4;13:261-271. doi: 10.2147/PGPM.S231471. eCollection 2020.
9
Pharmacogenetics of Pediatric Asthma: Current Perspectives.
Pharmgenomics Pers Med. 2020 Mar 18;13:89-103. doi: 10.2147/PGPM.S201276. eCollection 2020.
10
FCER2 T2206C variant associated with FENO levels in asthmatic children using inhaled corticosteroids: The PACMAN study.
Clin Exp Allergy. 2019 Nov;49(11):1429-1436. doi: 10.1111/cea.13460. Epub 2019 Aug 26.

本文引用的文献

1
Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children.
J Allergy Clin Immunol. 2008 Oct;122(4):741-747.e4. doi: 10.1016/j.jaci.2008.08.021.
2
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007.
J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. doi: 10.1016/j.jaci.2007.09.043.
3
FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma.
J Allergy Clin Immunol. 2007 Dec;120(6):1285-91. doi: 10.1016/j.jaci.2007.09.005. Epub 2007 Nov 5.
4
The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial.
J Allergy Clin Immunol. 2007 Jan;119(1):73-80. doi: 10.1016/j.jaci.2006.10.035.
5
Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma.
Pediatrics. 2006 Aug;118(2):e347-55. doi: 10.1542/peds.2005-2962. Epub 2006 Jul 24.
6
Bronchodilation and bronchoconstriction: predictors of future lung function in childhood asthma.
J Allergy Clin Immunol. 2006 Jun;117(6):1264-71. doi: 10.1016/j.jaci.2006.01.050. Epub 2006 Apr 27.
7
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma.
J Allergy Clin Immunol. 2005 Feb;115(2):233-42. doi: 10.1016/j.jaci.2004.11.014.
9
Significant variability in response to inhaled corticosteroids for persistent asthma.
J Allergy Clin Immunol. 2002 Mar;109(3):410-8. doi: 10.1067/mai.2002.122635.
10
Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids.
Am J Respir Crit Care Med. 2001 Feb;163(2):406-12. doi: 10.1164/ajrccm.163.2.9912091.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验